Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.56 |
| ▸ | HTR1A | P08908 | 4/20 | 0.55 |
| ▸ | DRD2 | P14416 | 4/20 | 0.55 |
| ▸ | KDR | P35968 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.48 |
| ▸ | CDK4 | P11802 | 1/20 | 0.48 |
| ▸ | CCND1 | P24385 | 1/20 | 0.48 |
| ▸ | CASP3 | P42574 | 1/20 | 0.48 |
| ▸ | CMA1 | P23946 | 1/20 | 0.48 |
| ▸ | MITF | O75030 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8335104 | 0.93 | HTR1A (0.50) | SIRT2HTR1ADRD2KDRMEN1 | |
| SCHEMBL8322554 | 0.88 | SIRT2 (0.74) | SIRT2HTR1ADRD2KDRMEN1 | |
| SCHEMBL9375258 | 0.83 | SIRT2 (0.49) | SIRT2HTR1ADRD2KDRMEN1 | |
| SCHEMBL14459912 | 0.82 | HTR1A (0.44) | SIRT2HTR1ADRD2KDRMEN1 | |
| SCHEMBL7198405 | 0.82 | SIRT2 (0.60) | SIRT2HTR1AKDRMEN1LMNA | |
| SCHEMBL8323398 | 0.78 | SIRT2 (0.59) | SIRT2HTR1ADRD2KDRMEN1 | |
| SCHEMBL28101300 | 0.77 | SIRT2 (0.58) | SIRT2HTR1ADRD2KDRMEN1 | |
| SCHEMBL8354023 | 0.77 | LMNA (0.50) | HTR1ADRD2MEN1LMNAMAPT | |
| SCHEMBL7816070 | 0.76 | CDK4 (0.78) | SIRT2KDRMEN1MAPTKMT2A | |
| SCHEMBL5434917 | 0.76 | SIRT2 (0.57) | SIRT2KDRMEN1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7262215-B2 | N-carbacycle monosubstituted indolocarbazoles as protein kinase inhibitors | NAD AG (DE) | 2007-08-28 | — | — | US | disclosed |
| US-7262215-B2 | N-carbacycle monosubstituted indolocarbazoles as protein kinase inhibitors | NAD AG (DE) | 2007-08-28 | — | — | US | disclosed |
| US-20070149481-A1 | N,n-bridged, nitrogen-substituted carbacyclic indolocarbazoles as protein kinase inhibitors | NAD AG (DE) | 2007-06-28 | — | — | US | disclosed |
| US-20070149481-A1 | N,n-bridged, nitrogen-substituted carbacyclic indolocarbazoles as protein kinase inhibitors | NAD AG (DE) | 2007-06-28 | — | — | US | disclosed |
| WO-2004048384-A1 | N,N-BRIDGED, NITROGEN-SUBSTITUTED CARBACYCLIC INDOLOCARBAZOLES AS PROTEIN KINASE INHIBITORS | NAD AG (DE) | 2004-06-10 | — | — | WO | disclosed |
| WO-2003051887-A1 | N-CARBACYCLE MONOSUBSTITUTED INDOLOCARBAZOLES AS PROTEIN KINASE INHIBITORS | NAD AG (DE) | 2003-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149481-A1 | N,n-bridged, nitrogen-substituted carbacyclic indolocarbazoles as protein kinase inhibitors | NIM1K, TNNI3K, MAP3K15 | SIRT2 1092/4885HTR1A 2912/4885DRD2 2658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.